ASH 2019 | CAR-T in myeloma: KarMMa and CRB-402 updates
Yi Lin
• 6 Dec 2019
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the current status, design and future of CAR T-cell therapy in multiple myeloma, including the KarMMa (NCT03361748) and CRB-402 (NCT03274219) studies. She highlights how while the products are still autologous, target BCMA and use a 4-1BB costimulatory domain, exposure to a p53 inhibitor during manufacture may give increased persistence. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
